semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Umbilical Cyst Pilonidal Sinus no limitation  patients followed-up less than 2 years
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Adult patients (18 years and older) Diagnosis of sickle cell disease by hemoglobin electrophoresis (HbSS, hematopoietic blood stem cell [HbSC], Sickle cell b0 Thalassemia, Sickle cell b+ Thalassemia) Able to give informed consent Any race/ethnicity/socioeconomic status  Pediatric patient (less than 18 years of age) Unable to give informed consent Untreated primary hyperparathyroidism (ICD9 codes 252.01XX and 252.00XX) hypercalcemia (serum calcium level > 11 mg/dl; ICD9 codes 275.42XX, 259.3XX, 252.00F) Pregnancy: a urine pregnancy test, or a serum pregnancy test, will be obtained at the time of enrollment in addition to reviewing the medical record; pregnant patients will be excluded because they should not undergo DXA scanning Patients taking atorvastatin, thiazide diuretics and digoxin, which are medications that can interact with vitamin D Non-English speakers
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Osteoarthritis Currently scheduled for a bone marrow aspirate concentration (BMAC) procedure Cognitively able to give consent and complete the required questionnaires  History of leukemia or lymphoma History of any autoimmune disorders and disease Currently taking immunosuppressive medications Presence of an active or suspected infection, or an infection of the joint in question within the past 6 months Vulnerable populations (pregnant women and breast-feeding women) Cortisone injection into the affected joint within 6 weeks Used NSAIDs within 1 week of the procedure History of bleeding disorders or inflammatory joint disease Surgical intervention on the affected or contralateral joint within 6 months of BMAC injection
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Medication-related Osteonecrosis of the Jaw Bisphosphonate-related Osteonecrosis of the Jaw Avascular Necrosis Stage 1, 2, or 3 MRONJ as defined by the AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update (Ruggiero 2014). 2. History of exposure to antiresorptive medications such as bisphosphonates or RANK-L inhibitors 3. Absence of tumor in the jaw at the time of recruitment 4. Patients with the capacity to give informed consent  Patients with history of external radiation therapy to the jaws 2. Patients who underwent any surgical intervention for MRONJ in the past 4 months 3. Patients with past microvascular reconstruction of the head and neck 4. Patients with an expected survival less than 1 year 5. Patients with allergy or hypersensitivity to pentoxifylline, xanthines, or tocopherol 6. Patients with planned invasive dental procedure in the next year 7. Patients taking oral anticoagulants 8. Patients with known hemorrhagic and coagulation disorder 9. Patients with a vitamin K deficiency due to any cause 10. Female patients who are pregnant or lactating 11. Patients with history of serious bleeding or extensive retinal hemorrhage 12. Patients with ischemic heart diseases, including, but not limiting, recent myocardial infarction 13. Patients with serious cardiac arrhythmia 14. Patient with history of prostate cancer 15. Patients with severe liver disease 16. Patients with severe renal failure (Creatinine clearance <30 mL/min) 17. Patients with diagnosed hypotension 18. Patients taking CYP1A2 inhibitors (e.g. ciprofloxacin, fluvoxamine) 19. Diagnosis of MRONJ with no exposed bone 20. Patient cannot tolerate impressions of exposed bone in a clinical setting, if needed. 21. There is a change in the patient's clinical presentation (tooth extraction, sequestrectomy) from alginate impression, if impression is indicated. 22. Any other situation or condition that, in the opinion of the may interfere with optimal in the study 23. A patient who has taken both bisphosphonate and Denosumab
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Schistosomiasis Adults, male, 18 to 49 years old (inclusive) at the time of inclusion Living in one of selected villages in Saint-Louis Region (Senegal) Free of obvious/severe health problems except schistosomiasis, as established by clinical examination and blood analysis, i.e. hematological exams, liver and renal function tests Written informed consent to participate obtained Treated with 40mg/kg Praziquantel (PZQ) before (W-5 to W-4 before the first injection) in case of infection with S. mansoni and S. haematobium Residence in the area during the period of the study  Adult who does not respond to one of the Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immuno-modifying drugs Known hypersensitivity to any component in the Sm14 vaccine or history of allergic disease Knowledge of non-infectious chronic disease Acute disease at time of enrollment Other conditions which in opinion of the PI may potentially represent a danger for the patient to be enrolled Non residence in the study area or intent to move during the study period
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tooth Impacted cases: bilateral wisdom tooth pathology control: agenesia/previous extraction/no symptoms of the lower third molars  younger than 18 years and older than 65 years pregnant or lactating females females using contraceptive methods suffering from any systemic illness undergoing any pharmacological treatment within 30 days prior to the patients affected by periodontal disease (radiographic diagnosis of vertical bone defects or bone resorption equal to 20% of the root length) patients with periapical and periradicular radiolucent areas X-ray detectable patients unable to participate to study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Systemic Inflammation Cardiopulmonary-bypass Undergoing cardiac surgery with planned cardiopulmonary bypass Additive Euroscore II ≥ 3 OR at least 3 surgical cardiac interventions are planned Ability to provide informed consent (not incapacitated)  Already on renal replacement therapy Patients with chronic kidney disease defined as estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 [ CKD stage > 3 ] Patients who are pregnant Concurrent enrollment in another clinical trial Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan Patients with ongoing infections or current use of steroids
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-103.0,  Missing Teeth Over 18 years old who are able to read and sign an informed consent form. 2. Patient who has good oral hygiene (Full-mouth plaque score <25%). 3. Subject would be available for study monitoring and follow-up visits. 4. Patients with missing teeth in the maxillary posterior region who will require sinus augmentation for implant placement. The patients may be partially or completely edentulous. 5. Patient is a candidate for delayed implant placement approximately 8 months following sinus grafting  Alcohol, drug dependency. 2. Signs or symptoms of chronic maxillary sinus disease. 3. Current smoker. 4. History of head and neck radiation treatment. 5. Poor health, conditions like uncontrolled diabetes, uncontrolled hypertension or other uncontrolled systemic disease. 6. Physical or psychological reason that might affect the surgical procedure or the subsequent prosthodontic treatment and/or required follow-up examinations. 7. Also, subjects who are nursing or pregnant will be excluded from the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Spinal Cord Injuries Osteoporosis Metabolic Syndrome Adult (age 18-60 years) Motor complete SCI (C1-T10 AIS A/B) years post-injury Have a telephone, and ability to attend the study visits Able to take oral medications and swallow independently Can provide free and informed consent Ability to understand instructions in English May report current use of oral alendronate 10mg daily or 70mg weekly or risedronate 5mg daily, 30mg weekly or 150mg monthly  These are intended to those in whom; Rosuvastatin would be unsafe, DXA/pQCT measurement or biomarker assessment would be invalid, or in whom other co-morbid health conditions may confound the study results Current and/or one year prior to enrolment treatment with any statin such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and rosuvastatin Current treatment with IV bisphosphonate, denosumab, recombinant PTH, ovarian hormone therapy, an oral contraceptive, Immunosuppressants (Including Cyclosporine) and fusidic acid Known allergy to Rosuvastatin, lactose powder, CoQ10, calcium carbonate, vitamin D2 and vitamin D3, or any other ingredient found in rosuvastatin, placebo or study supplements History of Paget's disease, osteomalacia, steroid induced osteoporosis, or untreated parathyroid or untreated thyroid disease Subjects with history of stage 4 chronic kidney disease. (124) Current Weight ≥136 kg Bilateral knee region metal implants (hardware), history of bilateral knee region contracture >30 degrees, fracture or any other bilateral knee region pathology which would preclude accurate DXA assessment of one limb Post-menopausal women (absence of menses for a minimum of 1 year) Women with amenorrhea due to bilateral surgical removal of the ovaries and/or uterus (women with amenorrhea due to spinal cord injury are able to participate)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Delayed Bleeding Post EMR Large Laterally Spreading Lesion in the Colon Endoscopic Mucosal Resection All patients referred for EMR of a LSL 20mm or larger Signed the informed consent  Clips used during the EMR procedure to close the defect, totally or partially Inadequate images to adequately assess the defect Use of blood thinners which have not been ceased according to the current guidelines for EMR
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Primary Biliary Cholangitis (PBC) Must have provided written informed consent 2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors History of elevated ALP levels for at least 6 months prior to Day 0 (randomization visit) Positive Anti-Mitochondrial Antibodies (AMA) titers (> 1/40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies Liver biopsy consistent with PBC 3. ALP >= 1.67x upper limit of normal (ULN) 4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening visit 5. Contraception: Females participating in this study must be of non-childbearing potential or must be using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment  History or presence of other concomitant liver diseases 2. Screening creatine phosphokinase (CPK) > upper limits of normal (ULN) 3. Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) > 5 ULN 4. Screening total bilirubin > 2 ULN 5. Screening serum creatinine > 1.5 mg/dl 6. Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney damage or estimated glomerular filtration rate [eGFR] of less than 60 mL/min/1.73 m^2). 7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh B/C) 8. Platelet count <150 X 10^3/microliter 9. Albumin <3.5 g/dL 10. Presence of clinical complications of PBC or clinically significant hepatic decompensation 11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating 12. Known history of human immunodeficiency virus (HIV) infection 13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Osteoarthritis, Knee >=3 months of symptomatic knee OA unresponsive to at least two of the following: activity modification, physical therapy, bracing, assistive devices, acupuncture, non-steroidal anti-inflammatory medications, local steroid injections, and hyaluronic acid injections Radiographically confirmed Kellgren-Lawrence I-II knee OA (mild knee OA; no bone-on-bone) Age 18-79 years  Presence of loose bodies on baseline magnetic resonance imaging Clinically and radiologically confirmed anterior/posterior cruciate ligament deficiences History of meniscal injury other than degenerative meniscal tears Previous knee surgery Presence of a degenerative meniscal tear causing mechanical symptoms such as locking, buckling, or give-way Intra-articular injection to affected knee within 6 weeks of intra-articular BMA injection Mechanical axis deviation greater than 7 degrees Intolerance to acetaminophen or hydrocodone (i.e., Vicodin) Use of non-steroidal anti-inflammatory drugs <1 weeks prior to BMA Injection of the joint scheduled for treatment within 3 months of BMA injection